A LPS targeting peptide based on specific anti-Gram-negative bacteria and its application
By modifying the 16-amino acid polypeptide AA16 of the CD14 protein and its derivative polypeptides, the antibacterial activity and specific binding to Gram-negative bacteria are enhanced, solving the problem of insufficient drugs for treating Gram-negative bacteria in the existing technology and achieving a highly efficient antibacterial effect.
Patent Information
- Application Number
- CN202310749460.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-25
- Publication Date
- 2025-09-19
- Estimated Expiration
- 2043-06-25
AI Technical Summary
In the prior art, there are few drugs for treating Gram-negative bacteria and their effects are limited. There is a lack of highly effective antibacterial agents, especially a lack of effective drugs for Gram-negative bacteria infections.
By intercepting and modifying the 16-amino acid peptide AA16 and its derivative peptides from the CD14 protein, the positive charge, hydrophobicity and α-helicity were enhanced to obtain LPS targeting peptides with specific binding and antibacterial activity against Gram-negative bacteria.
The obtained peptide showed good antibacterial activity and low hemolytic toxicity against Gram-negative bacteria, especially the minimum inhibitory concentrations against P. aeruginosa and E. coli were 32 μg/mL and 16 μg/mL, respectively, and the inhibitory concentration against Gram-positive bacteria was higher than 128 μg/mL, showing a specific antibacterial effect against Gram-negative bacteria.